Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma

Molecular Carcinogenesis

Volumn 49, Issue 9, 2010, Pages 810-817

  Zhu, Jian ^a   Qin, Chao ^a   Wang, Meilin ^a   Yan, Fu ^a   Ju, Xiaobing ^a   Meng, Xiaoxin ^a   Ding, Qi ^a   Li, Pu ^a   Yang, Jian ^a   Cao, Qiang ^a   Zhang, Zhengdong ^a   Yin, Changjun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Gene polymorphism; Genetic susceptibility; RCC

Indexed keywords

FAS ANTIGEN; FAS LIGAND; CASPASE 8;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASP8 GENE; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; AGED; APOPTOSIS; ASIAN; CASE CONTROL STUDY; CELL DEATH; GENETICS; MIDDLE AGED; RISK;

ADULT; AGED; APOPTOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CASPASE 8; CELL DEATH; FAS LIGAND PROTEIN; FEMALE; GENES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 77956222754     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20656     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005;14:243-250.
3. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176:2353-2358.
4. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: The multiethnic cohort. Am J Epidemiol 2007;166:932-940. (Pubitemid 47511687)
5. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
6. Raff M. Cell suicide for beginners. Nature 1998;396:119-122.
7. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: A review. J Cell Biochem 2003;88:885-898.
8. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004;9:691-704.
9. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-348.
10. Heikaus S, Kempf T, Mahotka C, Gabbert HE, Ramp U. Caspase-8 and its inhibitors in RCCs in vivo: The prominent role of ARC. Apoptosis 2008;13:938-949.
11. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-8633. (Pubitemid 38019198)
12. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998;8:1001-1008.
13. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
14. Lee SH, Shin MS, Park WS, et al. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 1999;59:3068-3072.
15. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-793. (Pubitemid 27381543)
16. Kim HS, Lee JW, Soung YH, et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 2003;125:708-715.
17. Soung YH, Lee JW, Kim SY, et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 2005;65:815-821.
18. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 1998;101:2579-2588.
19. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-1082. (Pubitemid 26313564)
20. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001;20:7437-7446.
21. Sun T, Gao Y, Tan W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007;39:605-613.
22. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-4330.
23. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132-138.
24. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-358.
25. Son JW, Kang HK, Chae MH, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet 2006;169:121-127.
26. Bethke L, Sullivan K, Webb E, et al. The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev 2008;17:987-989.
27. Frank B, Bermejo JL, Hemminki K, et al. Re: Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2005;97:1012; author reply 1012-1013.
28. Frank B, Hemminki K, Wappenschmidt B, et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis 2006;27:606-609.
29. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-582. (Pubitemid 27512871)
30. Mahfoudh W, Bel Hadj Jrad B, Romdhane A, Chouchane L. A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels. Int J Immunogenet 2007;34:209-212.
31. Li C, Wu W, Liu J, et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: A case-control analysis. Pharmacogenet Genomics 2006;16:245-251.
32. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442. (Pubitemid 38443646)
33. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-795.
34. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-776.
35. Wang M, Zhang Z, Tian Y, Shao J, Zhang Z. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res 2009;15:2567-2572.
36. Yang M, Sun T, Wang L, et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008;14:3230-3236.
37. Li C, Zhao H, Hu Z, et al. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat 2008;29:1443-1451.
38. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-325.
39. Kanemitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183-1188.
40. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479-484.
41. Zhang B, Sun T, Xue L, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-1073.
42. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030-1036. (Pubitemid 39162646)
43. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003;193:70-781.
44. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002;80:131-137.
45. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 2003;3:745-756.